重组人脑利钠肽对脓毒症合并心肾综合征患者的治疗作用

刘光发; 陈伟雄; 胡慧芳; 陈鹏; 吴湘; 何永祥

doi:10.13201/j.issn.1009-5918.2020.06.012

重组人脑利钠肽对脓毒症合并心肾综合征患者的治疗作用

- 粤北人民医院急诊科(广东韶关, 512026)
基金项目:
2020年度韶关市卫生健康科研项目(No:167)

详细信息

通讯作者: 刘光发,E-mail:lgfdnlr1253@163.com

中图分类号: R631.2

收稿日期: 2020-03-20

Therapeutic effect of recombinant human brain natriuretic peptide on patients with sepsis and cardiorenal syndrome

- Department of Emergency, North Guangdong People's Hospital, Shaoguan, Guangdong, 512026, China

More Information

Corresponding author: LIU Guangfa, E-mail: lgfdnlr1253@163.com

Received Date: 20 March 2020

摘要

摘要: 目的:探讨重组人脑利钠肽(rhBNP)对脓毒症合并心肾综合征患者的治疗效果及安全性。方法:以我院2017-03—2019-05期间的86例脓毒症合并心肾综合征患者为研究对象,随机分为对照组(43例)和观察组(43例);对照组给予抗感染、心肾功能不全等治疗,观察组在对照组基础上另给予rhBNP治疗;对比2组心、肾功能、血浆及预后指标。结果:治疗4周后,观察组心脏指数(CI)[(4.23±1.25)L/min·m²]、左室射血分数(LVEF)[(39.18±5.54)%]明显高于对照组[(3.74±0.92)L/min·m²,(35.34±5.67)%],观察组外周血管阻力指数(SVRI)[(1 847.36±172.59)dyn·s/(cm⁵·m²)]明显低于对照组[(2 102.27±183.38)dyn·s/(cm⁵·m²)](均P<0.05)。治疗4周后,观察组血肌酐(Scr)[(103.24±22.18)μmol/L]、BUN[(8.63±1.47)μmol/L]明显低于对照组[(143.66±24.57)μmol/L,(11.58±1.96)μmol/L],观察组肾小球滤过率(GFR)[(44.26±5.71)mL/min)]明显高于对照组[(38.84±5.56)mL/min)](均P<0.05)。治疗4周后,观察组血浆氨基末端B型利钠肽前体(NT-proBNP)[(3 516.14±947.23)ng/L)]、降钙素原(PCT)[(0.06±0.02)ng/mL)]、Lac[(0.92±0.25)mmol/L]明显低于对照组[(3 972.23±916.24)ng/L,(2.32±1.94)ng/mL,(1.45±0.31)mmol/L](均P<0.05)。观察组ICU住院时间[(11.3±1.5)d]明显低于对照组[(14.2±1.6)d](P<0.05);观察组4周病死率(39.53%)低于对照组(58.14%),但差异无统计学意义(P>0.05)。结论:rhBNP能够促进脓毒症合并心肾综合征患者心肾功能指标恢复,并降低患者脓毒症状,改善患者预后,值得在临床中推广应用。
- 脓毒症 /
- 心肾综合征 /
- 重组人脑利钠肽 /
- 疗效 /
- 安全性
Abstract: Objective: To investigate the therapeutic effect and safety of recombinant human brain natriuretic peptide in patients with sepsis and cardiorenal syndrome. Method: From March 2017 to May 2019 in our hospital, 86 patients with sepsis and cardiorenal syndrome were randomly divided into the control group(43 cases) and the observation group(43 cases). Treatments for cardiac and renal insufficiency were given in control group, and the observation group was given rhBNP treatment on the basis of the control group; the heart, kidney function, plasma and prognostic indicators of the two groups were compared. Result: After 4 weeks of treatment, the CI[(4.23±1.25)L/min·m²] and LVEF[(39.18±5.54)%] in the observation group were significantly higher than those in the control group[(3.74±0.92)L/min·m²,(35.34±5.67)%], and the SVRI in the observation group[(1 847.36±172.59)dyn·s/(cm⁵·m²)]was significantly lower than that in the control group[(2 102.27±183.38)dyn·s/(cm⁵·m²)](all P<0.05). After 4 weeks of treatment, Scr[(103.24±22.18)μmol/L] and BUN[(8.63±1.47)μmol/L] in the observation group were significantly lower than those in the control group[(143.66±24.57)μmol/L,(11.58±1.96)μmol/L], and GFR in the observation group[(44.26±5.71)mL/min)] was significantly higher than that in the control group[(38.84±5.56)mL/min)](all P<0.05). After 4 weeks of treatment, NT-proBNP[(3 516.14±947.23)ng/L)], PCT[(0.06±0.02)ng/mL)], and Lac[(0.92±0.25)mmol/L]were significantly lower in the observation group than those in the control group[(3 972.23±916.24)ng/L,(2.32±1.94)ng/mL,(1.45±0.31)mmol/L](all P<0.05). The number of days of ICU stay in the observation group[(11.3±1.5)d]was significantly lower than that in the control group[(14.2±1.6)d](P<0.05); the 4-week mortality rate(39.53%) in the observation group was lower than that in the control group(58.14%), but the difference was not obvious(P>0.05).Conclusion: rhBNP can promote the recovery of heart and kidney function indexes in patients with sepsis and cardiorenal syndrome, and reduce the sepsis symptoms and improve the prognosis of patients. It is worthy of popularization and application in clinical.
- sepsis /
- heart and kidney syndrome /
- recombinant human brain natriuretic peptide /
- efficacy /
- safety

HTML全文

参考文献(17)

[1]	潘灵爱,黄晓波.左西孟旦联合重组人脑利钠肽治疗脓毒症心功能障碍的疗效及其对短期预后的影响[J].实用心脑肺血管病杂志,2019,27(1):104-107.
[2]	蒲虹,黄晓波.重组人脑利钠肽对脓毒症诱导心功能障碍的影响[J].临床麻醉学杂志,2016,32(3):213-216.
[3]	Jonathan AS,Emmet M,Andrew JF,et al.Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness:a systematic review and meta-analysis[J].Intensive Care Med,2017,43(2):155-170.
[4]	丁莉,胡怡倩,卞雯,等.炎症因子对重症肺部感染合并脓毒症患者预后的评估价值[J].中华医院感染学杂志,2019,29(16):2418-2421.
[5]	及孟,李光智,余洪,等.破格救心汤联合重组人脑利钠肽对急性心力衰竭患者心功能及血清BNP、CK-MB和cTnI水平的影响[J].中国中医急症,2019,12(9):1524-1527.
[6]	章明,张健,郝淑新,等.重组人脑利钠肽应用于高龄患者心力衰竭的疗效及安全性[J].武警医学,2019,30(9):745-748.
[7]	杨昆,郭新宁,洪欣,等.重组人脑利钠肽治疗慢性肺心病急性加重期的临床效果及对5-HT浓度的影响[J].河北医科大学学报,2019,40(10):1217-1220.
[8]	Shakoory B,Carcillo JA,Chatham WW,et al.Interleukin-1 Receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome:,reanalysis of a prior phase Ⅲ trial[J].Crit Care Med,2016,44(2):275-281.
[9]	苏景丽.重组人脑利钠肽治疗急性心肌梗死合并心力衰竭效果观察[J].河南医学研究,2017,26(20):111-112.
[10]	郝艳敏,滑俊峰,王宇彤,等.重组人脑利钠肽对急性心力衰竭患者血浆半乳糖凝集素-3、内皮素-1、胱抑素C水平及心功能的影响[J].临床急诊杂志,2016,17(6):462-465.
[11]	Virzì GM,de Cal M,Day S,et al.Pro-apoptotic effects of plasma from patients with cardiorenal syndrome on human tubular cells[J].Am J Nephrol,2015,41(6):474-484.
[12]	王德国,王星,王新,等.重组人脑利钠肽对中重度心力衰竭患者自主神经功能的影响[J].临床血管病杂志,2012,28(4):255-258.
[13]	李建彬,吴强,林宇鹏,等.重组人脑利钠肽治疗老年心肾综合征的疗效观察[J].岭南急诊医学杂志,2016,21(1):35-37.
[14]	Carvajal JA,Ferrer FA,Araya FI,et al.Normal amino-terminal pro-brain natriuretic peptide(NT-proBNP)values in amniotic fluid[J].Clin Biochem,2016,50(1-2):23-26.
[15]	陈瑞娟,付斌,吴泽,等.血清Cys C指导下肾替代治疗脓毒症合并多器官功能障碍综合征的疗效研究[J].河北医学,2018,264(6):47-51.
[16]	孙丽君,薛澄,孙海棚,等.心脏手术术前血清脑钠肽与术后急性肾损伤的相关性分析[J].第二军医大学学报,2015,36(5):560-563.
[17]	胡星,潘传亮,刘剑萍,新活素静脉泵入对冠状动脉搭桥术后患者急性肾损伤的防治作用观察[J].山东医药,2017,57(39):71-73.